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ORIGINAL ARTICLE
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Background: Predicting vaccine efficacy against emerging pathogen strains is a significant problem in human and animal vaccine design. T-cell epitope cross-conservation
may play an important role in cross-strain vaccine efficacy. While influenza A virus

3

(IAV) hemagglutination inhibition (HI) antibody titers are widely used to predict pro-

4

tective efficacy of 1 IAV vaccine against new strains, no similar correlate of protection
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has been identified for T-cell epitopes.
Objective: We developed a computational method (EpiCC) that facilitates pairwise
comparison of protein sequences based on an immunological property—T-cell epitope
content—rather than sequence identity, and evaluated its ability to classify swine IAV
strain relatedness to estimate cross-protective potential of a vaccine strain for circulating viruses.
Methods: T-cell epitope relatedness scores were assessed for 23 IAV HA sequences
representing the major H1 swine IAV phylo-clusters circulating in North American
swine and HA sequences in a commercial inactivated vaccine (FluSure XP®). Scores
were compared to experimental data from previous efficacy studies.
Results: Higher EpiCC scores were associated with greater protection by the vaccine
against strains for 23 field IAV strain vaccine comparisons. A threshold for EpiCC relatedness associated with full or partial protection in the absence of cross-reactive HI
antibodies was identified. EpiCC scores for field strains for which FluSure protective
efficacy is not yet available were also calculated.
Conclusion: EpiCC thresholds can be evaluated for predictive accuracy of protection
in future efficacy studies. EpiCC may also complement HI cross-reactivity and phylogeny for selection of influenza strains in vaccine development.
KEYWORDS

computational immunology, hemagglutinin, influenza A viruses, swine influenza H1 viruses, swine
leukocyte antigen, T-cell epitope content comparison, T-cell epitope prediction, vaccine efficacy

1 | INTRODUCTION

production.1 Predicting whether existing vaccines will protect
against newly emergent strains circulating in pig herds is a signif-

Influenza A viruses (IAVs) cause a highly contagious respiratory

icant problem for pork producers. Hemagglutinin (HA) and neur-

disease in swine, a problem that has a significant impact on food

aminidase (NA) are the 2 major surface glycoproteins that define

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
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IAV subtypes and play a key role in antigenicity, pathogenesis, host

vaccinated with a commercial inactivated vaccine and challenged with

range, and protection in the context of vaccination. The segmented

heterologous H1N1 IAV when cross-reactive antibodies were absent.

IAV genome allows for antigenic shift by reassortment of RNA seg-

EpiCC differs from strict sequence-
based methods for compar-

ments from different viral strains infecting the same cell, generating

ing vaccine and outbreak strains. It uses PigMatrix, an algorithm that

novel viruses.2 Antigenic drift due to accumulation of mutations in

predicts class I and II T-cell epitopes specific to swine MHC (Swine

2

HA and NA contributes to the remarkable diversity of IAVs and im-

Leukocyte Antigen, SLA) alleles20 while also analyzing the TCR-facing

pedes the development of broadly effective IAV vaccines for both

residues of T-cell epitopes, to predict and assess epitope similarities

pigs and humans.

between input pathogen protein sequences. PigMatrix and associated

Currently, H1N1, H1N2, and H3N2 are the predominant IAV sub-

tools that comprise the iVAX vaccine design toolkit were previously val-

types cocirculating in the North American swine population. These

idated in retrospective and prospective studies of SLA-restricted influ-

subtypes are further subdivided based on the genetic and antigenic

enza epitopes.21,22 Here, we used EpiCC to determine the T-cell epitope

properties of HA. For H1 viruses, 7 distinct genetic phylo-clusters (α,

relatedness of HA proteins from 23 swine IAV strains representing the

β, γ, γ-2, δ1, δ2, and pandemic (pdm09)) have been identified.3 The HA

major H1 phylo-clusters circulating in the North American swine popula-

gene of α, β γ, and pdm09 cluster viruses is most similar to classical

tion. As the internal genes in North American swine influenza have been

swine H1N1 (cH1N1).3 HA from human-origin δ viruses can be dif-

highly conserved between strains since 1998 (due to the emergence of

ferentiated in 2 subclusters, δ1 and δ2.4 Due to antigenic variability of

the triple-reassortant internal gene [TRIG] cassette), we assumed mini-

HA, serological cross-reactivity between H1 clusters similar to cH1N1

mal T-cell epitope differences in those antigens and focused our analysis

is variable, and there is very limited serologic cross-
reactivity be-

instead on the critical and most variable swine IAV antigen, HA.3,23,24

3,5

Comparing the results of previously performed vaccine efficacy studies

Whether for swine IAV or for human IAV, methods for predicting

with IAV EpiCC scores, we were able to identify a level of T-cell epitope

whether a vaccine will protect against emerging IAVs, when serological

relatedness for a γ-cluster H1N1 vaccine virus that could be associated

cross-reactivity is absent, are needed.

with full or partial vaccine efficacy for this set of 23 IAV strains.

tween these viruses and the even more divergent δ cluster viruses.

Most of the North American commercial vaccines against swine
IAV contain inactivated viruses. The predominant antibody responses
induced by these vaccines are to the HA protein.1,6 Therefore,
hemagglutination-
inhibiting (HI) antibody titers, in addition to sequence analysis of HAs, are used to evaluate the potential for 1 vaccine

2 | METHODS
2.1 | Sequences

to protect against variant strains.6 However, full or partial protection in

Hemagglutinin sequences from 23 H1 IAV strains were included in the

pigs can still be observed (based on reduction in lung lesions and viral

analysis (Table 1). Sequences were either obtained from GenBank or

titers) following vaccination with inactivated commercial vaccines, de-

provided by Zoetis. Twenty of these HA sequences were from swine

spite the absence of cross-reactive antibodies post-vaccination.1,6-12

H1 viruses representing the α, β, γ, γ-2, δ1, δ2, and pdm09 phylo-

Protection in the absence of neutralizing antibodies is attributed to

clusters, and 3 of the sequences were from strains (belonging to the

T cell–mediated responses to cross-conserved T-cell epitopes.13,14 For

γ, δ1, and δ2 H1 phylo-clusters) included in FluSure XP (FS; Zoetis

example, in humans, immunity to cross-conserved epitopes during the
2009 H1N1 IAV pandemic may have contributed to attenuation of mor13,15

bidity in some age groups.

In mice, a DNA vaccine based on 8 HA T-

cell epitopes and 1 NA epitope that were conserved between seasonal

Inc., Florham Park, NJ, USA). Phylogenetic analysis was performed the
using MEGA7.25 All 23 HA amino acid sequences were aligned with
MUSCLE, and an evolutionary tree was defined using the maximum-
likelihood method with 500 bootstrap replicates.

and pdm09 strains lowered lung viral loads in HLA-DR3 transgenic mice
challenged with pdm09 in the absence of antibody responses.16 Other
murine studies have shown that cross-protection induced by conserved

2.2 | MHC binding prediction

antigens does not provide complete protection against infection, but

The HA amino acid sequences of the 23 IAV strains were screened using

reduces mortality, morbidity, virus replication, and viral shedding.17,18

PigMatrix.20 PigMatrix parses sequences into 9-mers and assesses the

Protection in these instances is believed to be due to the recognition

binding potential of each 9-mer i to SLA class I and II alleles. For each

of conserved, linear T-cell epitopes presented by class I or class II major

individual allele a in a set of MHC alleles A, PigMatrix raw scores r are

histocompatibility complex (MHC) molecules to cytotoxic T lympho-

normalized to Z-scores using the average μ and the standard deviation

cytes (CTL, CD8) and T-helper (Th, CD4) lymphocytes.19
As T-cell epitopes that are similar in vaccine and challenge strains

σ of scores calculated for 100 000 random 9-mers as previously de-

scribed for EpiMatrix (a human T-cell epitope prediction tool).26

may be responsible for protection in the absence of cross-reactive antibodies, we developed a method for T-cell epitope content comparison (EpiCC) that assesses the relatedness of class I and II epitopes
across antigens and predicts potential vaccine efficacy based on a

Z(i)a =

(r − μ)
σ

In this normalized set of scores for each SLA allele, 9-mers with Z-

relatedness threshold. Using this method, we evaluated whether T-

scores above 1.64 comprise the top 5% of sequences with significant

cell epitope relatedness could explain protection of pigs that were

SLA binding potential. Increasing Z-scores correlate with higher MHC

|
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TABLE 1
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Hemagglutinin sequence information for swine H1 influenza A viruses

Virus namea

Labelb

Virus H1 cluster

GenBank accession
or sourcec

A/swine/Iowa/15/1930 (H1N1)

Classical

IA30 cH1

EU139823

A/swine/Illinois/02450/2008 (H1N1)

α

IL08 H1α

CY099052

A/swine/South Dakota/A01823598/2015 (H1N2)

α

SD15 H1α

KT356682

A/swine/St-Hyacinthe/106/1991 (H1N1)

α

SH91 H1α

U11857

A/swine/Iowa/40766/1992 (H1N1)

α

IA92 H1α

KP788773

A/swine/Minnesota/00040/2002 (H1N1)

β

MN02 H1β

Zoetis

A/swine/Iowa/00239/2004 (H1N1)

β

IA04 H1β

KM198690

A/swine/Iowa/110600/2000 (H1N1)

γ

IA00 H1γ FS

Zoetis

A/swine/Minnesota/PAH618/2011 (H1N1)

γ

MN11 H1γ

Zoetis

A/swine/Ohio/02973/2010 (H1N1)

γ

OH10 H1γ

Zoetis

A/swine/Iowa/A01940123/2015 (H1N1)

γ

IA15 H1γ

KT699044

A/swine/Minnesota/A01940015/2015 (H1N1)

γ

MN15 H1γ

KT595733

A/swine/Iowa/A01410129/2012 (H1N1)

γ2

IA12 H1γ-2

KJ397936

A/California/04/2009 (H1N1)

H1N1pdm09

CA09 H1pdm

GQ117044

A/swine/Oklahoma/0726H/2008 (H1N2)

δ1

OK08 H1δ1 FS

Zoetis

A/swine/Ontario/55383/04 (H1N2)

δ1

ON04 H1δ1

DQ280212

A/swine/Illinois/PAH710/2011 (H1N2)

δ1

IL11 H1δ1

Zoetis

A/swine/South Dakota/A01823304/2015 (H1N2)

δ1

SD15 H1δ1

KT277819

A/swine/Oklahoma/A01566774/2014 (H1N2)

δ1

OK14 H1δ1

KP270784

A/swine/Minnesota/A01823864/2015 (H1N2)

δ1

MN15a H1δ1

KT699050

A/swine/Iowa/A01823426/2015 (H1N2)

δ1

IA15 H1δ1

KT356694

A/swine/Minnesota/A01940042/2015 (H1N2)

δ1

MN15b H1δ1

KT733589

A/swine/North Carolina/031/2005 (H1N1)

δ2

NC05 H1δ2 FS

Zoetis

A/swine/NC/00573/2005 (H1N1)

δ2

NC05 H1δ2

FJ638306

a

FS viruses are shown in bold font.
FS viruses have “FS” at the end of their labels.
c
Sequences marked “Zoetis” were provided by Zoetis and are considered proprietary.
b

binding probability. The same thresholds for defining low, medium,
and high probability MHC binders are applied as have been previously
used in EpiMatrix studies.26

2.3 | T-cell epitope content comparison
EpiCC assesses the relatedness of T-cell epitopes contained in a

The distribution of SLA alleles among pig herds in the United States

protein sequence of a strain s and those contained in a protein se-

is unknown. Binding was therefore predicted to a set of SLA class I

quence of a vaccine strain v based on a comparison of the epitope

and II alleles that were frequently expressed in a cohort tested in a

sequences and their PigMatrix SLA binding score, using a set of

previous study (SLA-I: SLA-1*0801, 1*1201, 1*1301, 2*0501, 2*1201,

MHC alleles A. For any comparison, T-cell epitopes can be either

3*0501, 3*0601, and 3*0701; SLA-II: SLA-DRB1*0201, 0402, 0602,

shared (conserved) between sequences, or unique to the strain, or

22

unique to the vaccine. Thus, the EpiCC score for the comparison

0701, and 1001).

As data are lacking on breadth of coverage for SLA (the ability

between s and v (EpiCC score or T-cell epitope-based relatedness)

for selected SLA alleles to cover an outbred population of pigs), the

is based on the PigMatrix scores of shared and unique epitopes (Fig.

set of sequences was also evaluated using HLA alleles for which the

S1).

27,28

We quantified the HLA-restricted

Intuitively, the epitope content of a protein depends on its epitope

T-cell epitopes that could be identified in these IAV sequences and

density. So, if a “high–epitope density” protein is compared to a highly

compared to the epitopes uncovered using the set of SLA selected

similar protein and many of their epitopes are conserved or shared

for this study. The breadth of coverage comparison was performed

between the 2 strains, the scores of shared epitopes will be high; con-

using the following HLA class I and class II supertype alleles: HLA-I:

sequently, the score of the comparison of their epitope content (EpiCC

A*0101, A*0201, A*0301, A*2402, B*0702, and B*4403; and HLA-II:

score) will also be high. As PigMatrix binding probabilities of s and v are

DRB1*0101, 0301, 0401, 0701, 1101, 1301, and 1501.29

considered for the calculation, the EpiCC score will be even higher if

breadth of coverage is known.
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the shared 9-mer epitopes have high predicted binding probabilities to

vaccine-unique if i and j are predicted to bind allele a, and their TCRf
are distinct. For i,j where both 9-mers are not predicted to bind allele

the alleles in the set A.
We hypothesized that if epitopes in a vaccine closely match the

a, S(i,j)a and U(i,j)a are undetermined.

epitopes in the challenge strain, and vaccine-and strain-unique epi-

As the alleles in A are distinct, they are treated independently;

topes are rare, the memory T cells induced by the vaccine are likely

hence, the score of shared epitopes for i,j over the full set of alleles can

to recognize the epitopes in the proteins of the challenge strain. The

be calculated as a joint probability (ie, product of the shared binding

model assumes (i) that there is no prior T-cell memory to the epitopes

probabilities for individual alleles). However, given that the score of a

(a naïve immune system); (ii) that vaccination does not induce memory

shared epitope is calculated only for i,j where both 9-mers are pre-

T cells to epitopes that are unique to the challenge strain; and (iii) that

dicted to be binders, the joint probability over multiple alleles under-

the efficacy of the vaccine might be adversely affected by the pres-

weights shared promiscuous epitopes. For this reason, we computed

ence of many vaccine-unique epitopes.30 Consequently, in our calcu-

the sum of the probabilities instead.

lation, the EpiCC score of 2 sequences is improved by the presence of

For the calculation of the EpiCC score, we assume that binding

shared epitopes but decreases with increasing numbers of strain-and

of each 9-mer epitope is mutually exclusive and uniform. Thus, E is

vaccine-unique epitopes. The impact of “unique” epitopes could be ad-

the sum of shared and unique epitope scores of each i,j normalized by

justed in future comparisons.

the total number of compared pairs p to account for variable epitope

The first step in calculating the EpiCC score is to obtain T-cell

densities, and by the number of MHC alleles in A allowing for compari-

epitope predictions for s and v using PigMatrix. Each 9-mer i∈s is

son of values of E determined using different numbers of MHC alleles.

compared to a corresponding 9-mer j∈v. The pairs of 9-mers i,j are de-

Formally, the EpiCC score for sequences from a vaccine and strain is

termined from a local alignment of s and v sequences using the Smith-

computed as:

Waterman algorithm from EMBOSS.31 For i,j where one of the 9-mers
E(s,v)A =

has a gap in position 1, that 9-mer is considered “nonexistent,” that is,
excluded from comparison.

∑∑
1
S(i,j)a − U(i,j)a
|p| ⋅ |A| iϵs;jϵv aϵA

For each of the pairs i,j and for each allele a∈A, the score of a

The sum of class I and II E(s,v)A is the total epitope-based related-

shared T-cell epitope S(i,j)a is computed only for epitopes that are

ness score for s and v. Note that U(i,j)a functions as a penalty; there-

cross-conserved (ie, i,j with identical residues that face the TCR and

fore, if U(i,j)a > S(i,j)a , E(s,v)A is negative.

predicted to bind to allele a). We reasoned that epitopes with iden-

Comparison of the predicted epitope content of any sequence

tical TCR-facing residues (TCRf), which are also predicted to bind

to itself defines the sequence’s baseline EpiCC score (E(s,s)A; Fig.

to the same MHC allele, are more likely to induce cross-reactive

S1) and it represents the predicted epitope density of the sequence

memory T cells. This is a simple assumption because a TCR can

and the binding probabilities of its epitopes. It follows that the

recognize peptides with different TCRf,

32

but it is a conservative

maximum value of any comparison between a vaccine strain and a

initial approach to define potential cross-reactive epitopes.33 For

challenge strain E(s,v)A can only be less than or equal to E(v,v)A or

class I T-cell epitope comparison, we assumed that i and j are cross-

E(s,s)A. For vaccines with low T-cell epitope content, the baseline

conserved, and potentially cross-reactive, if they have identical res-

EpiCC score E(v,v)A will be low, and the comparison score E(s,v)A

idues in positions 4, 5, 6, 7, and 8 and are predicted to bind to a,

will be also low, even if s and v epitopes are highly similar. Thus,

regardless of differences on their MHC-facing amino acids. For class

low E(s,v)A can be due either to low T-cell epitope content of 1

II, amino acids in positions 2, 3, 5, 7, and 8 were considered TCRf.

or both sequences and/or to low epitope relatedness between the

Positions were selected based on published analysis of peptide-

strains.

MHC-TCR crystal structures.

34

S(i,j)a is calculated using predicted

binding probabilities as follows:
S(i,j)a = p(i)a ⋅ p(j)a

2.4 | HA baseline EpiCC score comparison
We calculated the baseline EpiCC score of the HA sequence of each

where p is the cumulative probability in the normal distribution for the

viral strain (E(s,s)A). So as to evaluate whether the selection of specific

Z-score. As the binding of i and j to allele a is independent, S(i,j)a, the

sets of MHC alleles had an effect on the baseline EpiCC scores, E(s,s)A

probability of them both occurring, is the product of the probabilities

was calculated using the epitope content predicted with 4 different

of each occurring (ie, joint probability).

sets of MHC alleles. Specifically, we compared EpiCC scores calcu-

The score of a unique epitope U(i,j)a is determined for non-cross-
conserved epitopes based on binding probabilities according to these

lated with swine allele sets SLA-I and SLA-II to EpiCC scores calculated with human allele sets HLA-I and HLA-II.

criteria:
1. Score of a strain-unique epitope: if Z(i)a > 1.64 → U(i,j)a = p(i)a
2. Score of a vaccine-unique epitope: if Z(j)a > 1.64 → U(i,j)a = p(j)a

2.5 | Comparison of HA T-cell epitope content
between field and vaccine viruses

Note that for any given i,j, predicted epitopes cannot be both

To test whether we could determine an EpiCC score that defined full

shared and unique for allele a, but they can be both strain-unique and

or partial protection, we compared the epitope content (predicted

|
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using SLA alleles) of each HA to that of FS vaccine viruses (E(s,v)A).
Shared and unique class I, class II and total EpiCC scores were
determined. We also explored the relationships between protein
identity and EpiCC scores using regressions. To represent the lower
end of the sequence identity spectrum, we included HA sequences
from A/Missouri/2124514/2006 (H2N3), A/Guangxi/592/2011
(H5N1), A/swine/Mexico/GtoDMZC02/2014 (H5N2), A/swine/
North Carolina/A01442548/2012 (H3N2), and A/swine/Missouri/
A01727926/2015 (H4N6) viruses (GenBank accessions EU258939,
KM027999, KU141372, KC445235, and KU641621, respectively);
their HA amino acid sequences had identities between 41.1% and
64.61% when compared to the sequence of HA from FS viruses.
A random sequence that had the same number of amino acids as
the average HA sequence in this data set and the average (natural)
amino acid frequencies of proteins in the Swiss-Prot database was
also included in the comparison.

2.6 | Relationship between EpiCC scores and
vaccine efficacy
The goal of this analysis was to determine whether a certain level of
T-cell epitope relatedness of HA could be associated with protection
afforded by vaccination in the absence of cross-reactive antibodies
in pre-challenge sera, assuming minimal variation in T-cell epitope
content among internal proteins. We therefore evaluated whether
the experimental outcomes of six previously performed FS H1N1γ
vaccination and H1N1 challenge studies could be predicted using a
defined EpiCC score threshold. For this analysis, FS was considered
to be protective if it significantly reduced the percentage of lung

535

3 | RESULTS
3.1 | Baseline EpiCC scores for E(s,s)A
HA amino acid sequences from different swine IAV phylo-clusters
(Figure 1) representing a range of sequence identities (from high to
low) were analyzed. Although inactivated whole-
virus vaccines for
influenza contain many antigens, the critical protective antigen (and
the most variable) is considered to be HA. Thus, for this analysis, we
calculated EpiCC for HA and did not include internal proteins in the
calculations. Across the 23 H1 viruses, baseline HA SLA class I EpiCC
scores, E(s,s)SLA-I, were significantly lower (P < .001) and less variable
(0.049 (0.001); mean (standard deviation)) than class II EpiCC scores
(E(s,s)SLA-II, 0.068 (0.004)) (Fig. S2A), and they were not significantly correlated (ρ = 0.18, P = .19). HA proteins from recently reported H1δ1
cluster viruses had the highest class II and total baseline EpiCC scores.

3.2 | SLA vs HLA
To evaluate the effect of allele specificity and the breadth of coverage of the set of SLA alleles, we compared the baseline EpiCC scores
predicted using SLA alleles to that predicted using human supertype
HLA alleles. The baseline class I HLA allele-defined EpiCC scores
(E(s,s)HLA-I, 0.063 (0.002)) were significantly higher (P < .001) than
those predicted using SLA alleles (E(s,s)SLA-I (0.049 (0.001); Fig. S2B).
Baseline HLA class II EpiCC scores (E(s,s)HLA-II (0.065 (0.004)) were
significantly lower (P < .05) than those predicted using SLA class II alleles (E(s,s)SLA-II (0.068 (0.004); Fig. S2C). The relevance of this finding
is unknown. The lower baseline scores observed for SLA class I alleles

lesions and viral titers in nasal swabs (ie, nasal shedding) and/or in
the lung or lung lavage. The EpiCC score threshold associated with
protection was defined as the lowest EpiCC score for the comparison between the FS H1γ vaccine virus and challenge viruses, where
studies demonstrated that the inactivated vaccine was protective.
EpiCC scoring was performed independently and prior to obtaining
information about the outcomes of the vaccination and challenge
studies.

2.7 | Statistical analysis
Wilcoxon matched-pairs signed rank test was used to compare baseline EpiCC score of HA sequences defined using different sets of MHC
alleles (eg, E(s,s)SLA-I vs E(s,s)SLA-II; E(s,s)SLA-I vs E(s,s)HLA-I). The same test
was applied to evaluate differences between SLA class I and II EpiCC
scores for each vaccine virus. Correlation between class I and II baseline EpiCC scores was determined using the nonparametric Spearman
correlation coefficient (ρ). Correlation of class I and II EpiCC scores
was evaluated using the same test. We used Pearson correlation (r)
to evaluate the relationship between sequence identity and EpiCC
scores. P-values (p) less than .05 were deemed significant. Analyses
were performed using R 3.3.1 (Foundation for Statistical Computing,
Vienna, Austria).

F I G U R E 1 Phylogenetic tree for the Hemagglutinin (HA) amino
acid sequences of influenza A field and FluSure vaccine (FS) viruses
representing H1 phylo-cluster in the North American swine.
Bootstrap test results are shown next to the branches
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as compared to HLA class I alleles may indicate that the set of SLA-I

cluster of the same HA lineage (cH1N1 or human seasonal) had higher

alleles selected for this study was not as broad in terms of population

scores for class I and II shared epitopes and lower scores for unique

coverage of swine, and might not capture all the T-cell epitope differ-

epitopes than viruses in clusters from a different HA lineage (Figure 2).

ences between strains. Alternatively, the HA sequences of the ana-

It is noteworthy that there were shared epitopes in all comparisons,

lyzed IAV may contain fewer epitopes that bind to SLA class I alleles.

even when comparing viruses from different HA lineages.

This could also be true for human class I epitope content in IAV, as

Scores of shared, strain–unique, and vaccine-unique SLA class II

the IAV strains had lower (P = .04) HLA class I baseline EpiCC scores

epitopes were significantly higher than those for SLA class I (P < .001

compared to those of HLA class II using supertype HLA alleles (Fig.

for the 3 vaccine viruses), except for scores of H1γ FS vaccine-unique

S2D). The number of reported class I epitopes defined for IAV in gen-

epitopes (P = .05). Likewise, using HLA supertype alleles, scores of

eral (based on published data in the Immune Epitope Database35) also

class II shared epitopes were also significantly higher than those for

seems to be lower than the number of epitopes defined in IAV that are

class I (P < .01; Fig. S3). Class II scores of unique epitopes were also

restricted by class II; thus, the differences described here are consist-

higher for OK08 H1δ1 FS (vaccine-unique) and NC05 H1δ2 FS (strain-

ent with previous observations and may be relevant to pathogenesis.

unique). As mentioned above, although the population coverage of the
set of SLA class I may be limited, the fact that the same lack of class
I epitopes was observed for HLA supertype alleles suggests that the

3.3 | Comparison of T-cell epitope content between
field and vaccine viruses

analyzed HA sequences had lower class I epitope content than class
II content.

We then compared the SLA class I and II epitope content predicted for

We used radar plots to facilitate the comparison of EpiCC scores

HA of each field virus to that of the vaccine viruses, E(s,v). Intuitively,

between the vaccine and challenge strains. The EpiCC scores are dis-

HA proteins from similar strains will have similar epitope content.

played on these plots as a distance along a radiating line that also pro-

Thus, HA sequences from viruses within the same H1 cluster or in a

vides information on the relative sequence identity of the individual

**

**

**

**

**

**

**

**

Strain
1:IA00 H1 FS

4:OH10 H1

7:IA15 H1

10:SH91 H1

13:SD15 H1

16:NC05 H1 2

19:IL11 H1 1

2:IA92 H1

5:CA09 H1pdm

8:IA04 H1

11:MN15 H1

14:IA30 cH1

17:OK08 H1 1 FS

20:OK14 H1 1

22:IA15 H1 1
23:SD15 H1 1

3:MN11 H1

6:IA12 H1 -2

9:MN02 H1

12:IL08 H1

15:NC05 H1 2 FS

18:ON04 H1 1

21:MN15a H1 1

24:MN15b H1 1

F I G U R E 2 Comparison of scores of shared and unique epitopes across strains. Scores of shared, vaccine-unique, and strain-unique swine
leukocyte antigen class I and II epitopes were determined for the comparison of hemagglutinin (HA) sequences from vaccine viruses and field
(challenge) strains. Note that y-axes show different scales. Solid connecting lines are included only for visualization purposes. P-values of
comparisons were calculated using 1-tailed Wilcoxon matched-pairs signed rank test (**P < .001). HA vaccine sequences had higher scores for
shared epitopes with strains belonging to the same H1 cluster or the same HA lineage. In general, scores of class II shared and unique epitopes
were significantly higher than those of class I. Viruses are sorted by nucleotide identity relative to H1γ FS. Strain numbers on the x-axis are
described in detail in the legend below
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strains in the comparisons. In Figure 3, each axis corresponds to 1

H1N1 γ-cluster vaccine strain (IA00 H1γ FS) against heterologous

virus HA sequence. The HA sequences are sorted clockwise by nu-

viruses representing α, β, γ, or H1pdm clusters (Table 2) to define a

cleotide identity, relative to the FS vaccine strain (IA00 H1γ FS virus).

threshold of HA T-cell epitope relatedness between vaccine and chal-

These radar plot figures highlight differences between EpiCC scores

lenge H1N1 strains that could be associated with protection. This in-

(distance) and sequence identity (see IA12 H1γ-2 and IA15 H1γ, for

formation was not provided prior to conducting the EpiCC scoring. The

example). The highest EpiCC score for each plot is given by E(v,v)A, that

primary measure for assessing vaccine efficacy in these studies was

is, vaccine compared to itself.

reduction in lung lesions; the reductions in viral nasal shedding and/or

We also found that the relationship between identity and EpiCC

virus titers in the lung or lavage fluid at necropsy were considered to

scores was nonlinear second-order polynomial (Figure 4; R2=0.94-0.98).

be secondary outcomes. The inactivated vaccine was considered pro-

Unlike identity, EpiCC scores reflect important differences in amino

tective in our analysis if there was a reduction in macroscopic pneu-

acids contained in predicted T-cell epitopes and do not attribute value

monia as well as reduction in virus titers in nasal swabs and/or in lung

to amino acids that are not found in epitopes. For example, there are

specimens collected at necropsy. If the vaccine significantly reduced

35 amino acids that differ between the vaccine strain IA00 H1γ FS

virus titers, but not lung lesions, it was considered partially protective.

and the field virus CA09 H1pdm, but only 16 of these amino acids

For the 6 vaccine efficacy studies considered in this analysis, FS

were involved in putative SLA binders and had an effect on the class

conferred protection against challenge with 5 different H1N1 cluster

II EpiCC score. Furthermore, only 4 of the residues were contained in

viruses (Table 2). In 5 of the 6 studies, protection was conferred de-

9-mers that were predicted to bind to 3 or more class II SLA alleles.

spite low levels of HI cross-reactive antibodies (HI GMT to challenge

Thus, EpiCC score may more accurately reflect relevant immunologi-

virus ≤20) measured at the day of the challenge. For these studies, the

cal identity between sequences. EpiCC scores for sequences that had

threshold associated with protective efficacy was defined as the low-

approximately 40% identity were no different from EpiCC scores for a

est total EpiCC score (EpiCC score of −0.001; MN02 H1β) comparing

random amino acid sequence of similar length. Similar results were ob-

these 5 challenge strains with the vaccine strain (IA00 H1γ FS). This

served for correlation with HA nucleotide sequence identity (Fig. S4).

threshold defines the white area in Figure 5. For strains with EpiCC
scores above the threshold, the scores of shared epitopes represented
at least 67% (0.076) of the vaccine’s baseline HA EpiCC score (0.114;

3.4 | Relationship between EpiCC scores and
vaccine efficacy

Table 1), which may suggest that a field virus or a vaccine strain (or
both) may have many unique epitopes, but as long as there is a suffi-

Having calculated the EpiCC scores for 23 IAV strains, we then used

cient level of shared epitopes relative to the baseline, an inactivated

the results of previously reported vaccine efficacy studies for the FS

vaccine will be protective.

IA00 H1γ FS

OK08 H1δ1 FS

NC05 H1δ2 FS

Class I EpiCC score

Class II EpiCC score

IA00 H1γ FS

IA00 H1γ FS
IA92 H1α
MN15b H1δ1 0.08
MN11 H1γ
SD15 H1δ1

MN15b H1δ1 0.08
SD15 H1δ1
0.04

IA15 H1δ1

IA92 H1α
MN11 H1γ
OH10 H1γ

0.00

MN15a H1δ1

CA09 H1pdm

IA15 H1δ1
MN15a H1δ1

– 0.04

OK14 H1δ1

– 0.12

ON04 H1δ1

IA12 H1γ-2

OK14 H1δ1

IA15 H1γ

IL11 H1δ1

IA04 H1β

OK08
OK08H1δ1
H1δ1 FS

MN02 H1β

NC05 H1δ2

SH91 H1α

NC05H1δ2
H1δ2 FS
NC05

IA30 cH1

SD15 H1α

OH10 H1γ

0.00

CA09 H1pdm

– 0.04

– 0.08

IL11 H1δ1

0.04

MN15 H1γ
IL08 H1α

IA12 H1γ-2

– 0.08

IA15 H1γ

– 0.12

IA04 H1β

ON04 H1δ1

MN02 H1β

OK08 H1δ1 FS

SH91 H1α

NC05 H1δ2
NC05 H1δ2 FS
IA30 cH1

SD15 H1α

MN15 H1γ
IL08 H1α

F I G U R E 3 EpiCC score comparisons between hemagglutinin (HA) sequences of FluSure vaccine (FS) viruses and field viruses. Each axis
corresponds to the HA sequence of 1 virus. EpiCC score = Scores of shared epitopes -Scores of strain-and vaccine-unique epitopes. HA
sequences in the same cluster had the highest EpiCC scores. For each vaccine virus, class I and II EpiCC scores were significantly different from
each other (P < .05). Note that for comparisons where the score for unique epitopes was greater than the score for shared epitopes, EpiCC
scores were below zero
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F I G U R E 4 Relationship between EpiCC scores and hemagglutinin (HA) amino acid identity. The second-order polynomial relationship
between class I (top) and II (bottom) EpiCC scores and amino acid identity for each FS virus is shown. R2 values of regression models are
shown. H2N3, H5N1, H5N2, H3N2, H4N6, and a random sequence were included in this analysis to represent the lower end of the identity
range. Interestingly, there were instances where viruses had low EpiCC scores despite high identity (eg, class II epitope content of IA00 H1γ FS
compared to SD15 H1α)
Additionally, the IA00 H1γ vaccine induced partial protection

above the threshold for partial protection. The low total EpiCC score

against challenge with IL08 H1α. This EpiCC score (−0.038) was con-

is driven by a low score for shared epitopes (0.069; 60.2%) and high

sidered a threshold associated with partial protection. This threshold

score for unique epitopes (0.092; Table 1). Nevertheless, shared epi-

separates the light gray from the dark gray area in Figure 5. IL08 H1α’s

topes between IA00 H1γ FS and IA12 H1γ-2 virus HA might still con-

shared epitopes score was 58.4% (0.066) of the vaccine’s baseline

tribute to a certain level of protection.

EpiCC score. EpiCC scores for the H1δ cluster viruses, IA30 cH1 and
SD15 H1α strains were below the partial protection threshold in the
dark gray area.

4 | DISCUSSION

Based on the association between total EpiCC scores of HA and
vaccine efficacy, we speculate that immunization with the IA00 H1γ

EpiCC is a method for assessing the relationship between field and

FS vaccine strain could confer protection against challenge with vi-

vaccine strains of pathogens using predicted T-cell epitope content

ruses with scores above −0.001 (white area in Figure 5) and partial

as a metric for comparison; here it is applied to IAV and vaccination/

protection for challenge-vaccine EpiCC scores between -0.001 and

challenge studies performed in swine. As compared to standard meth-

−0.038 (light gray area in Figure 5), assuming minimal variation in inter-

ods for estimating vaccine efficacy, such as determining whether im-

nal antigens. Although specific vaccine efficacy data were not available

munization induces cross-reactive antibodies to the HA proteins, or

for heterologous challenges performed with viruses for which EpiCC

measuring genetic differences by sequence similarity, EpiCC charac-

scores fall in the dark gray area of Figure 5, we would hypothesize that

terizes the differences based on portions of the virus that the immune

the vaccine might not be protective against these strains. Important

system processes and presents to T cells that drive potentially protec-

differences between strain identity and EpiCC scores can be identi-

tive responses.

fied; for example, the nucleotide sequence of IA12 H1γ-2 virus HA

In our first test of the EpiCC scoring system, we compared the

is highly identical to IA00 H1γ FS (93.36%); however, its total EpiCC

T-cell epitope content of 20 HA sequences from different H1 clus-

score (−0.023) is below the threshold associated with protection, but

ters present in the North American swine population to that of 3 HA
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TABLE 2
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FluSure XP® vaccination and H1N1 challenge studies

Heterologous
challenge

Measurement of protectiona

H1N1 Virus

Percentage of
macroscopic
pneumonia

Virus titers in nasal
swabs

Virus titers in lungs

MN02 H1β

Reduced

Reduced

IA92 H1α

Significantly reduced

CA09 H1pdm

Significantly reduced

OH10 H1γ

HI GMT to
challenge
(vaccine)b
virus

Outcomec

Ref.

Not available

80 (381)

Protection

7

5.38

Significantly reduced

Not available

≤20 (320)

Protection

9

1.61

Significantly reduced

Significantly reduced

≤10 (53d)

Protection

6

0.63

Significantly reduced

Not available

Significantly reduced

≤10 (109)

Protection

10

1.64

MN11 H1γ

Significantly reduced

Significantly reduced

Significantly reduced

≤20 (117)

Protection

11

2.10

IL08 H1α

Not significantly
different

Significantly reduced

Significantly reduced

≤20 (240)

Partial protection

12

-1.34

Total EpiCC
score
(×102)

a

Significance of outcomes was as measured and reported in the original references.
HI GMT to the challenge and homologous viruses are shown.
c
The vaccine was considered protective if it reduced macroscopic pneumonia and virus titers in nasal swabs and/or in lungs collected at necropsy. If the
vaccine significantly reduced virus titers, but not lung lesions, it was considered partially protective.
d
HI GMT to a heterologous γ-cluster virus (A/Swine/OH/51145/2007 H1N1).
b

outcomes of efficacy studies of FS H1N1γ vaccine virus where protection was induced in the absence of high levels of cross-reactive HA antibodies. The results of the analysis, performed without foreknowledge
of efficacy outcomes, showed a threshold of T-cell epitope relatedness
that explained protection.
We do not yet know whether the threshold score would apply
to new strains or different vaccines. The thresholds described in this
study were based on experimental data from only 6 vaccine efficacy
studies against challenge with cH1N1-
lineage viruses. Additional
efficacy studies would help to refine and validate the thresholds
for prediction of protection and partial protection as well as lack of
protection, and permit the evaluation of permutations of the EpiCC
calculation. In this version of the EpiCC calculation we prioritized epitope content shared between sequences and penalized strain-and
vaccine-unique epitopes; this is based on an assumption that response
to shared epitopes is protective while response to unique epitopes is
not, which may not be entirely true. Further studies will be required
F I G U R E 5 Definition of threshold for prediction of vaccine
efficacy prediction. Total EpiCC scores (sum of class I and II EpiCC
scores; blue line) for the comparison of H1γ FS and each viral strain
are shown. The FS γ-cluster vaccine strain was protective or partially
protective against challenge with viruses annotated as (P) or (PP),
respectively. The rest of the viruses were not tested as challenge
strains. Protection and partial protection thresholds (black lines)
defined 3 areas shown in white (protection; total EpiCC score above
−0.001), light gray (partial protection), and dark gray (no protection).
Viruses used to set the thresholds are marked with an asterisk (*). We
hypothesize that FS would confer at least partial protection against
challenge with viruses that had EpiCC scores outside the darker gray
region

to extend these findings to other IAV strains, to determine whether
EpiCC scores can be used to define thresholds of vaccine efficacy for
other important swine pathogens, and whether EpiCC could be used
to select influenza strains for human vaccines.
We note that the set of MHC alleles used for the prediction of
epitopes influenced the scores of shared and unique epitopes, and
therefore the EpiCC scores, between vaccine strains and field viruses.
To illustrate this point, baseline EpiCC scores calculated using binding
predictions to SLA alleles were shown to be different from those determined using a set of supertype HLA alleles. EpiCC scores for SLA-I
alleles were significantly lower than those for HLA-I alleles and SLA-
II-based scores were higher than HLA-II EpiCC scores. For this study,
SLA allele selection was based on frequencies determined using low-

sequences from H1 viruses contained in a commercial swine IAV in-

resolution haplotyping for a small number of pigs.22 The relevance of

activated vaccine. To evaluate whether T-
cell epitope relatedness

these differences using distinct sets of MHC alleles is unknown; how-

between vaccine and non-homologous challenge strains was associ-

ever, the distribution of SLA alleles for the North American swine pop-

ated with protection, we compared EpiCC scores with experimental

ulation has yet to be defined, and therefore, the EpiCC scores might be
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different using a more comprehensive set of alleles. Development of a

subunit CA09 H1pdm vaccine elicited robust HA-specific CD4 T-cell

high-throughput SLA typing system paired with a systematic study of

responses dominated by memory CD4 T cells specific for peptides

SLA diversity would improve the utility of the EpiCC analysis for swine

shared between the seasonal and pandemic strain.42 Researchers

populations not only for IAV, but also for other economically important

also demonstrated that expansion of CD4 T cells specific for peptide

pathogens affecting the swine industry. EpiCC scores were developed

epitopes within HA, but not NP, correlated with neutralizing antibody

for populations of swine (and humans). Some vaccines may be more or

response.42 These results support the notion that a greater degree of

less protective for a given individual, depending on the EpiCC scores

CD4 T-cell cross-reactivity (and higher class II EpiCC scores) may be

for that individual’s SLA (or HLA) alleles.

associated with improved antibody response.

In this case study, we were unable to determine which compo-

T cell–mediated responses directed to the conserved internal

nent of the score (shared class II epitopes or shared class I epitopes,

proteins of influenza viruses may have contributed to protection, as

for example), is more important for predicting protection. Published

epitopes are more highly cross-conserved than the epitopes found in

information describing T cell–dependent (CMI) responses elicited by

HA.43,44 In pigs, 2 evolutionary lineages (H1pdm09 and TRIG) domi-

swine IAV vaccines is scarce and some studies have reported that CMI

nate the selection of internal genes in the circulating influenza viruses,

However,

leading to a high degree of conservation in the internal genes.3,23,24 We

other studies showed that inactivated vaccines can prime the

have previously identified highly conserved SLA-restricted epitopes

CD4 + CD8 + (double-positive) memory T-cell subset.9,37,38 Porcine

in the NA and M proteins that are found in different IAV subtypes.22

CD4 + CD8 + T cells are MHC class II-restricted memory cells that

Other groups have also reported conserved SLA class I-restricted epi-

express perforin and mediate cytolytic activity against virus-infected

topes in NA.45,46 This EpiCC analysis focuses on HA (while disregarding

responses to inactivated vaccines can be limited in pigs.

39,40

36

For the set of alleles used for epitope prediction in this anal-

conserved internal and other external genes), as much of the antigenic

ysis, we found higher scores for class II epitopes shared between vac-

variability between IAV strains circulating in swine (and differences in

cines and field virus HAs compared to those of class I. Should further

protection by vaccine strains) is localized to the HA surface antigen.

studies determine that cross-reactive class II epitopes are more rele-

Moreover, the predominant antibody response induced by inactivated

vant for protection with inactivated vaccines, a weighted EpiCC score

vaccines is driven by antibodies to the HA protein. Therefore, these re-

that favors class II epitopes could be applied.

sults are most relevant to inactivated vaccines, whole virus and HA sub-

cells.

Based on these findings, EpiCC scores showing high levels of T-

unit vaccines, and vectored vaccines containing the HA protein. Future

cell epitope relatedness support the hypothesis that T-cell responses

studies will compare the utility of including other surface antigens (such

are involved in protection against challenge that is observed in the ab-

as NA and M2) in the EpiCC score to determine whether thresholds re-

sence of HI cross-reactivity in experimental efficacy studies of the FS

vealed by HA-specific T-cell epitope relatedness can be further refined.

γ-cluster vaccine virus. The IA00 H1γ FS vaccine virus is clearly genet-

Genetic sequence comparison of HA is also used for predicting

ically and antigenically (by HI titer) distinct from the challenge viruses

potential cross-protective efficacy of vaccines. The relationship be-

used in the 6 experimental challenge studies for which efficacy data

tween EpiCC scores and HA amino acid sequence identity was non-

were available. However, under the conditions of these experimental

linear. At approximately 40% identity, epitope-based relatedness was

studies, vaccination with FS provided protection or partial protection

similar to the EpiCC score of a random amino acid sequence of the

against MN11 H1γ, IA92 H1α, OH10 H1γ, and CA09 H1pdm with

same length. And while changes in amino acids affecting T-cell epi-

HI titers lower than 1:40 (the cutoff generally considered predictive

topes can have a significant impact on the immunogenicity of an an-

of protection by antibodies).6,9-11 We observe that MN11 H1γ, IA92

tigen,47,48 their effect on whole antigen sequence similarity may be

H1α, and OH10 H1γ had the highest EpiCC scores among evaluated

minimal. To illustrate this point, we found viruses that had low EpiCC

HA sequences when compared to IA00 H1γ FS; CA09 H1pdm had the

scores despite having high sequence identity. For example, when

sixth highest score. Among these H1N1 viruses, only IA92 H1α and

IA00 H1γ FS is compared to IA12 H1γ-2, the nucleotide identity is

CA09 H1pdm have different internal genes.3 IA92 H1α predates the

93.36% and the EpiCC score is above the threshold set for partial

emergence of TRIG, and CA09 H1pdm was classified as a swine-origin

protection, but below the threshold for protection. Although H1γ-2

IAV because internal and HA gene segments were genetically similar

cluster viruses were infrequently detected in the US swine popula-

to those in the triple-reassortant viruses circulating in North American

tion, characterization of H1γ-2 viruses demonstrated divergent anti-

swine.41 Some differences in strain-specific T-cell epitope content of

genic properties with viruses within the same clade and viruses from

internal proteins should be expected. Notwithstanding these potential

contemporary swine H1 clusters as well as commercial vaccines, sug-

differences in the internal genes, the IA00 H1γ FS vaccine was protec-

gesting a potential risk of vaccine failure against some H1γ-2 viruses.3

tive against challenge with both strains.

6,9

This result may suggest that

On the contrary, EpiCC analysis suggests that the H1γ cluster vaccine

a certain level of shared T-cell epitopes could be associated with pro-

virus may induce at least partial protection against IA12 H1γ-2 virus.

tection, despite the presence of unique epitopes. Antibodies to other

In conclusion, we developed the EpiCC algorithm to assess the immu-

surface antigens, such as NA, may have also played a role in protection.

nological relatedness between vaccines and emerging pathogen antigens

The role of T-
cell epitopes in the highly variable external IAV

based on their predicted T-cell epitope content. Using EpiCC in a case

protein, HA in protection against influenza in pigs is not yet known;

study of swine influenza viruses, we found that vaccine protection con-

however, human studies showed that vaccination with a monovalent

ferred by the FS IA00 H1 γ-cluster, in the absence of HI cross-reactive
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antibodies, might be explained by predicted T-cell epitope content relatedness between challenge and vaccine viruses. Based on these results, we
proposed EpiCC score thresholds for prediction of full and partial protection. EpiCC scores were dependent on a set of swine MHC alleles used for
the predictions of epitopes; thus, future EpiCC scores for these sequences
may differ from the scores reported here. As information about SLA prevalence in North American swine populations becomes available, the impact of MHC allele selection on EpiCC scores will be assessed further.
This study provides preliminary evidence that EpiCC may complement current methods (HI cross-reactivity and phylogenetic analysis) for
selecting the best-matched vaccine virus for immunization against emerging swine IAVs. Additional data from vaccine efficacy studies in swine and
other species will be useful to validate and optimize these thresholds and
extend the usefulness of EpiCC to other human and swine pathogens and
available (or future) vaccines.
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